CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway

MeSH terms

• Adenine / analogs & derivatives
• Antineoplastic Agents / pharmacology
• Casein Kinase II / antagonists & inhibitors*
• Casein Kinase II / metabolism
• Drug Synergism
• Hematologic Neoplasms / drug therapy*
• Hematologic Neoplasms / metabolism
• Humans
• Immunoglobulin G / pharmacology
• Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
• Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
• Naphthyridines / pharmacology*
• Phenazines
• Piperidines
• Prognosis
• Purines / pharmacology
• Pyrazoles / pharmacology
• Pyrimidines / pharmacology
• Quinazolinones / pharmacology
• Receptors, Antigen, B-Cell / antagonists & inhibitors*
• Receptors, Antigen, B-Cell / immunology
• Receptors, Antigen, B-Cell / metabolism
• Signal Transduction / drug effects*
• Vidarabine / analogs & derivatives*
• Vidarabine / pharmacology